Second, since PD-1 is absent on naive immune cells, selective targeting spares the naive lymphocyte pool, preserving immune repertoire diversity and reducing the risk of long-term immunodeficiency—a major limitation of traditional immunosuppressants such as teplizumab.61 Here, PDCD1 is linked to immunodeficiency disease.